Literature DB >> 2416842

T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat.

R R Caspi, F G Roberge, C G McAllister, M el-Saied, T Kuwabara, I Gery, E Hanna, R B Nussenblatt.   

Abstract

Long-term S-antigen (S-Ag)-specific T lymphocyte lines were derived from the lymph nodes of immunized Lewis rats that had been pretreated with low-dose cyclophosphamide. The protocol consisted of functional selection by alternating cycles of stimulation with S-Ag presented on syngeneic accessory cells and proliferation in IL 2-containing spleen-conditioned medium, coupled with early phenotypic selection for cells bearing the helper/inducer membrane marker (W3/25), by panning on antibody-coated plastic dishes. This protocol consistently resulted in the rapid generation of in vivo functional cell lines capable of mediating experimental autoimmune uveoretinitis (EAU) when transferred into naive rats at 5 to 10 X 10(6) cells/rat systemically or 1 to 2 X 10(6) cells/rat intravitreally. The disease appeared within 6 to 8 days, usually with minimal anterior chamber involvement, and was often unilateral. Pathologic changes resembled those seen in EAU induced by active immunization. The disease could be transferred without concomitant formation of serum antibodies. The uveitogenic line cells were negative for Ia antigen and positive for the W3/25 membrane marker, which appeared to be stable in long-term culture. They proliferated vigorously in vitro and produced IL 2 in response to S-Ag or Con A, but not to unrelated antigens. The establishment of uveitogenic T helper lymphocyte lines will permit the analysis of the cellular mechanisms involved in EAU in a more defined system than has been available.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416842

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

Review 1.  Immune mechanisms in uveitis.

Authors:  R R Caspi
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

3.  A bird in the hand.

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 4.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

5.  IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses.

Authors:  Reiko Horai; Mary J Mattapallil; Wai Po Chong; Phyllis B Silver; Jun Chen; Ru Zhou; Yuri Sergeev; Rafael Villasmil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Autoimmun       Date:  2013-09-07       Impact factor: 7.094

Review 6.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats.

Authors:  S M Robertson; L S Lang
Journal:  Agents Actions       Date:  1994-10

Review 8.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  The relationship between HTLV-I-infected cell lines and uveitis.

Authors:  A Fukushima; H Ueno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-04       Impact factor: 3.117

10.  Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis.

Authors:  D G Charteris; S L Lightman
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.